Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Teitelbaum

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
BMC Cancer|January 8, 2022
Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementationKelsey S Lau-Min, Lisa A Varughese, Maria N Nelson, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 10, 1996
Effects of protein calorie malnutrition on tuberculosis in miceJ Chan, Y Tian, K E Tanaka, et al.
Cancer|November 21, 2015
The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN)Matthew T McMillan, Russell S Lewis, Jeffrey A Drebin, et al.
Clinical Nuclear Medicine|August 19, 2015
Peptide Receptor Radionuclide Therapy-Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine TumorsBrian P Riff, Yu-Xiao Yang, Michael C Soulen, et al.
The Oncologist|July 22, 2020
Phase II Trial of Palbociclib in Patients with Advanced Esophageal or Gastric CancerThomas Benjamin Karasic, Mark H O'Hara, Ursina R Teitelbaum, et al.
Clinical and Translational Science|January 7, 2026
Consent, Concern, and Capacity: Factors Associated With Attitudes Toward Pharmacogenetic Testing Among Patients With Gastrointestinal CancerArravinth Anantharajah, Raza Chaudhry, Victoria A Wittner, et al.
Cardiovascular and Interventional Radiology|December 6, 2023
Integrated Capecitabine-Temozolomide with Radioembolization for Liver-Dominant G2 NETs: Long-Term Outcomes of a Single-Institution Retrospective StudyMichael C Soulen, Ursina R Teitelbaum, Rosemarie Mick, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 20, 2000
Granulysin, a T cell product, kills bacteria by altering membrane permeabilityW A Ernst, S Thoma-Uszynski, R Teitelbaum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 29, 2013
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinomaGregory L Beatty, Drew A Torigian, E Gabriela Chiorean, et al.
Cancer Reports (Hoboken, N.J.)|June 17, 2021
Quantifying the impact of the COVID-19 pandemic on gastrointestinal cancer care deliveryNicholas R Perkons, Casey Kim, Chris Boedec, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
BMC Cancer|January 8, 2022
Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementationKelsey S Lau-Min, Lisa A Varughese, Maria N Nelson, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 10, 1996
Effects of protein calorie malnutrition on tuberculosis in miceJ Chan, Y Tian, K E Tanaka, et al.
Cancer|November 21, 2015
The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN)Matthew T McMillan, Russell S Lewis, Jeffrey A Drebin, et al.
Clinical Nuclear Medicine|August 19, 2015
Peptide Receptor Radionuclide Therapy-Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine TumorsBrian P Riff, Yu-Xiao Yang, Michael C Soulen, et al.
The Oncologist|July 22, 2020
Phase II Trial of Palbociclib in Patients with Advanced Esophageal or Gastric CancerThomas Benjamin Karasic, Mark H O'Hara, Ursina R Teitelbaum, et al.
Clinical and Translational Science|January 7, 2026
Consent, Concern, and Capacity: Factors Associated With Attitudes Toward Pharmacogenetic Testing Among Patients With Gastrointestinal CancerArravinth Anantharajah, Raza Chaudhry, Victoria A Wittner, et al.
Cardiovascular and Interventional Radiology|December 6, 2023
Integrated Capecitabine-Temozolomide with Radioembolization for Liver-Dominant G2 NETs: Long-Term Outcomes of a Single-Institution Retrospective StudyMichael C Soulen, Ursina R Teitelbaum, Rosemarie Mick, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 20, 2000
Granulysin, a T cell product, kills bacteria by altering membrane permeabilityW A Ernst, S Thoma-Uszynski, R Teitelbaum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 29, 2013
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinomaGregory L Beatty, Drew A Torigian, E Gabriela Chiorean, et al.
Cancer Reports (Hoboken, N.J.)|June 17, 2021
Quantifying the impact of the COVID-19 pandemic on gastrointestinal cancer care deliveryNicholas R Perkons, Casey Kim, Chris Boedec, et al.
Pageof 4